评估三种基于血凝素的疫苗在骡鸭中实验性控制泛动物流行2.3.4.4b分支A(H5N8)高致病性禽流感病毒的效果
2016-2017年冬季法国检测到487起2.3.4.4b分支H5N8亚型高致病性禽流感疫情。研究在骡鸭中评估三种血凝素疫苗对H5N8高致病性禽流感病毒攻击的保护效果,结果显示Vac1几乎完全阻断口咽和泄殖腔排毒,Vac3仅阻断泄殖腔排毒,Vac2仅部分减少呼吸道和肠道排毒。
要点
- Vac1(3周龄注射,或1日龄首免后加强)几乎阻断口咽和泄殖腔排毒。
- Vac3(3周龄单次注射)仅阻断泄殖腔排毒,部分减少呼吸道排毒。
- Vac2(2周龄单次注射)仅部分减少呼吸道和肠道排毒。
核心结论
- Vac1 abolished oropharyngeal and cloacal shedding to almost undetectable levels, whereas Vac3 abolished cloacal shedding only and Vac2 only partly reduced respiratory and intestinal excretion.
- These results provided relevant insights in the immunogenicity of recombinant H5 vaccines in mule ducks.
研究设计与样本
- 研究在受控条件下评估三种疫苗对骡鸭的保护效果,骡鸭为北京鸭与番鸭的杂交种。
- Vac1源自另一2.3.4.4b分支A(H5N8)高致病性禽流感病毒的血凝素基因,3周龄注射(单独或1日龄首免后加强)。
- Vac2为商业二价佐剂疫苗,含源自2.3.2分支A(H5N1)高致病性禽流感病毒的修饰血凝素,2周龄单次注射。
- Vac3含同源2.3.4.4b H5血凝素基因,3周龄单次注射。
- 鸭6周龄时用A/decoy duck/France/161105a/2016 (H5N8)高致病性禽流感病毒攻击。
主要发现
- 攻击后每2-3天监测病毒排毒,持续两周,采用实时逆转录聚合酶链反应和血清学分析(H5N8血凝抑制试验、H5 ELISA和AIV ELISA)。
- Vac1使口咽和泄殖腔排毒降至几乎检测不到的水平。
- Vac3仅阻断泄殖腔排毒,同时部分减少呼吸道排毒。
- Vac2仅部分减少攻击病毒的呼吸道和肠道排毒。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In France during winter 2016-2017, 487 outbreaks of clade 2.3.4.4b H5N8 subtype high pathogenicity (HP) avian influenza A virus (AIV) infections were detected in poultry and captive birds. During this epizootic, HPAIV A/decoy duck/France/161105a/2016 (H5N8) was isolated and characterized in an experimental infection transmission model in conventional mule ducks. To investigate options to possibly protect such ducks against this HPAIV, three vaccines were evaluated in controlled conditions. The first experimental vaccine was derived from the hemagglutinin gene of another clade 2.3.4.4b A(H5N8) HPAIV. It was injected at three weeks of age, either alone (Vac1) or after a primer injection at day-old (Vac1 + boost). The second vaccine (Vac2) was a commercial bivalent adjuvanted vaccine containing an expressed hemagglutinin modified from a clade 2.3.2 A(H5N1) HPAIV. Vac2 was administered as a single injection at two weeks of age. The third experimental vaccine (Vac3) also incorporated a homologous 2.3.4.4b H5 HA gene and was administered as a single injection at three weeks of age. Ducks were challenged with HPAIV A/decoy duck/France/161105a/2016 (H5N8) at six weeks of age. Post-challenge virus excretion was monitored in vaccinated and control birds every 2-3 days for two weeks using real-time reverse-transcription polymerase chain reaction and serological analyses (haemagglutination inhibition test against H5N8, H5 ELISA and AIV ELISA) were performed. Vac1 abolished oropharyngeal and cloacal shedding to almost undetectable levels, whereas Vac3 abolished cloacal shedding only (while partially reducing respiratory shedding) and Vac2 only partly reduced the respiratory and intestinal excretion of the challenge virus. These results provided relevant insights in the immunogenicity of recombinant H5 vaccines in mule ducks, a rarely investigated hybrid between Pekin and Muscovy duck species that has played a critical role in the recent H5 HPAI epizootics in France.
引用
- Niqueux É, Flodrops M, Allée C, et al. Evaluation of three hemagglutinin-based vaccines for the experimental control of a panzootic clade 2.3.4.4b A(H5N8) high pathogenicity avian influenza virus in mule ducks. Vaccine. 2022. PMID: 36411134. doi:10.1016/j.vaccine.2022.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。